Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 133

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 133
---

    )

    (1,466,337
    ) 

    (83
    )%

    Other expense

    (218,516
    )

    (7,533
    )

    (210,983
    ) 

    (2,801
    )%

    Net loss before provision for income taxes

    (3,448,939
    )

    (1,771,619
    )

    (1,677,320
    )

    (95
    )%

    Provision for income taxes

    —

    —

    —

    NA

    Net loss
     
    $
    (3,448,939
    )

    (1,771,619
    )

    (1,677,320
    )

    (95
    )%

36 

Operating
Expenses

Our
operating expenses consist of general and administrative expenses, research and development expenses and professional fees.

General
and Administrative Expenses

We
incurred general and administrative expenses for the three months ended June 30, 2025 and 2024 of $1,110,084 and $1,209,874, respectively.
For the three months ended June 30, 2025, compared to the same period in 2024, this represented a decrease of $99,790, or 8%,
primarily as a result of a decrease of $108,535 in D&O insurance.

Research
and Development Expenses

We
incurred research and development expenses for the three months ended June 30, 2025 and 2024 of $514,814, and $12,955, respectively.
For the three months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $501,859, or 3,874%,
with the details set forth in the table below:

    Three
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    Consultant
     
    $
    107,408

    $
    107,357

    $
    51

    0
    %

    Lab Gas

    457

    1,452

    (995
    )

    (69
    )%

    Lab Cell Storage

    15,795

    27,272

    (11,